DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zelboraf (Vemurafenib) - Current Clinical Trials

 
 



Zelboraf Related Clinical Trials

Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer [Recruiting]

The Safety and Efficacy Study of Vemurafenib (CT) Compared With Vemurafenib (Zelbolaf�) in Advanced Patients Harboring the V600 BRAF Mutation [Active, not recruiting]

Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas [Recruiting]

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma [Terminated]

Study of Vemurafenib, Carboplatin, and Paclitaxel [Recruiting]

BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia [Recruiting]

Sorafenib or Crizotinib and Vemurafenib in Advanced Cancer [Recruiting]

Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer [Recruiting]

Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases [Recruiting]

Vemurafenib, Cetuximab, and Irinotecan in Advanced Solid Cancers [Recruiting]

Study for the Evaluation of Vemurafenib ( Zelboraf® ) and Ipilimumab ( Yervoy® ) in Combination With DNE3 Therapy to Patients With Metastatic Melanoma [Terminated]

Bioavailability Study of Vemurafenib in Patients With BRAF^V600 Mutation-Positive Malignancies [Recruiting]

Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations [Recruiting]

The Effects of Vemurafenib on Immunity in Patients With Melanoma [Recruiting]

Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma [Recruiting]

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma [Recruiting]

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma [Not yet recruiting]

Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379 [Recruiting]

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery [Terminated]

Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases [Completed]

A Clinical Trial to Evaluate a Helper Peptide Vaccine Plus Vemurafenib in Melanoma [Not yet recruiting]

A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma [Completed]

Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study [Recruiting]

Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study [Recruiting]

Vemurafenib Plus Cobimetinib in Metastatic Melanoma [Recruiting]

The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma [Recruiting]

Study of the Combination Vemurafenib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation [Recruiting]

Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases [Not yet recruiting]

Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases [Withdrawn]

Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma [Suspended]

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma [Recruiting]

A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients [Recruiting]

Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib [Active, not recruiting]

Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib [Recruiting]

Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer [Completed]

Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation [Terminated]

Vemurafenib and TIL Therapy for Metastatic Melanoma [Recruiting]

Vemurafenib and White Blood Cell Therapy for Advanced Melanoma [Active, not recruiting]

A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer [Completed]

Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) [Terminated]

Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor [Active, not recruiting]

A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma [Completed]

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy [Completed]

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma [Terminated]

An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol [Recruiting]

Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients [Completed]

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma [Active, not recruiting]

BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma [Recruiting]

A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy [Recruiting]

A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma [Withdrawn]

Neoadjuvant Vemurafenib + Cobimetinib in Melanoma: NEO-VC [Recruiting]

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma [Recruiting]

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy [Completed]

A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies [Completed]

A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma [Active, not recruiting]

coBRIM: A Phase 3 Study Comparing GDC-0973 (Cobimetinib), a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma [Active, not recruiting]

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma [Active, not recruiting]

A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers [Recruiting]

Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma [Active, not recruiting]

A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma [Active, not recruiting]

An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma [Active, not recruiting]

A Study of Zelboraf (Vemurafenib) in Chinese Patients With BRAFV600 Mutation-Positive Unresectable or Metastatic Melanoma [Active, not recruiting]

A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafenib (Zelboraf®) or Vemurafenib Plus Cobimetinib in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma [Recruiting]

BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma [Recruiting]

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E [Completed]

A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients [Recruiting]

Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity [Not yet recruiting]

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation [Suspended]

A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma [Recruiting]

Safety Study of PLX4032 in Patients With Solid Tumors [Active, not recruiting]

A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma [Completed]

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases [Active, not recruiting]

A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma [Completed]

A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf, and Erivedge Treatment Targeted Against Certain Mutations in Cancer Patients [Recruiting]

Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma [Completed]

BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations [Recruiting]

Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease [Recruiting]

A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3) [Active, not recruiting]

Radiation Use During Vemurafenib Treatment [Not yet recruiting]

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma [Completed]

A Study of RO5185426 (Vemurafenib) in Patients With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation [Active, not recruiting]

A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma [Completed]

A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib [Withdrawn]

A Study of RO5185426 in Patients With Metastatic Melanoma [Active, not recruiting]

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib) [Completed]

A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases [Completed]

An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS) [Recruiting]

A Study of RO5185426 in Patients With Metastatic Melanoma [No longer available]

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib [Terminated]

Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma [Recruiting]

A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer [Recruiting]

A Multi-Center Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer [Recruiting]

Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. [Recruiting]

N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy [Recruiting]

Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease [Recruiting]

Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes [Recruiting]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017